News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eidogen's Target Informatics Platform Pilot Licensed By Boehringer Ingelheim GmbH



10/19/2005 5:10:38 PM

PASADENA, Calif.--(BUSINESS WIRE)--March 30, 2004--Eidogen, Inc., a biotechnology company committed to developing the finest computational drug discovery platforms, announces today that Boehringer Ingelheim has agreed to pilot license Eidogen's Target Informatics Platform(TM) (TIP(TM)) software. TIP is the industry's first structural informatics enterprise software solution that successfully bridges the gap between bioinformatics and cheminformatics. Eidogen's Pilot License program offers prospective customers the opportunity to use TIP for a limited period at a reduced cost. "This is another significant milestone for Eidogen; it demonstrates that major pharmaceutical companies see real value in the in-silico chemogenomics discovery strategy enabled by TIP," said Derek Debe, Eidogen's Co-Founder and CEO. "We are excited to be working with Boehringer Ingelheim."

About Eidogen, Inc.

Eidogen is a Pasadena, California-based company committed to delivering the finest computational drug discovery platforms ever developed. Eidogen's Target Informatics Platform (TIP) supports new and truly collaborative research in target prioritization, lead discovery, and lead optimization, enabling drug discovery organizations to effectively attack their druggability, selectivity, toxicity, and reduced market exclusivity problems. Please visit www.eidogen.com to learn more.

About Boehringer Ingelheim

The Boehringer Ingelheim Corporation is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 156 affiliates in 44 countries and more than 32,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2002, Boehringer Ingelheim posted net sales of 7.6 billion euro while spending about one fifth of net sales in its largest business segment Prescription Medicines on research and development. Please visit www.boehringer-ingelheim.com to learn more.

Contacts

Eidogen, Inc. Sean Mullen, 626-817-2208 sean@eidogen.com or

Alan Herman & Assoc. Janet Roberts, 949-443-1695 janet@ahamar.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES